TDO2 Recombinant antibody, PBS Only (Capture)

TDO2 Uni-rAbTM Recombinant Antibody for WB, Cytometric bead array, Indirect ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, rat

Applications

WB, Cytometric bead array, Indirect ELISA

Conjugate

Unconjugated

CloneNo.

240068C2

Cat no : 83236-2-PBS

Synonyms

TRPO, TPH2, TO, TDO, EC:1.13.11.11



Product Information

83236-2-PBS targets TDO2 as part of a matched antibody pair:

MP00219-1: 83236-2-PBS capture and 83236-1-PBS detection (validated in Cytometric bead array)

MP00219-2: 83236-2-PBS capture and 83236-3-PBS detection (validated in Cytometric bead array)

Unconjugated rabbit recombinant monoclonal antibody in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation. Created using Proteintech’s proprietary in-house recombinant technology. Recombinant production enables unrivalled batch-to-batch consistency, easy scale-up, and future security of supply.

This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.

Tested Reactivity human, rat
Host / Isotype Rabbit / IgG
Class Recombinant
Type Antibody
Immunogen TDO2 fusion protein Ag8531
Full Name tryptophan 2,3-dioxygenase
Calculated Molecular Weight 406 aa, 48 kDa
Observed Molecular Weight 40-50 kDa
GenBank Accession NumberBC005355
Gene Symbol TDO2
Gene ID (NCBI) 6999
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

TDO2 (tryptophan 2,3-dioxygenase), IDO1 (indoleamine 2,3-dioxygenase 1) and IDO2 are three enzymes that catalyze the amino acid tryptophan into kynurenine in the kynurenine pathway (PMID: 23090118, 28469468). TDO2 plays an important role in neurological diseases such as Alzheimer's disease, Parkinson's disease and autism. Overexpression of TDO2 promoted tumor cell survival and was correlated with tumor grade and poor prognosis in triple negative breast cancer, brain tumors and esophageal squamous cell carcinoma. TDO2 may be a potential therapeutic target in some cancers. (PMID: 21976023, 30134247)